Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041299 | 0.83 | ESR1 (0.47) | MEN1KMT2ANPSR1POLBTSHR | |
| SCHEMBL15478368 | 0.81 | MEN1 (0.42) | MEN1KMT2ANPSR1KIF11CYP1A2 | |
| SCHEMBL7037051 | 0.79 | MEN1 (0.50) | MEN1KMT2ANPSR1CYP1A2POLB | |
| SCHEMBL22654049 | 0.79 | MEN1 (0.50) | MEN1KMT2ANPSR1CYP1A2POLB | |
| SCHEMBL10691417 | 0.77 | MEN1 (0.48) | MEN1KMT2ANPSR1CYP1A2POLB | |
| SCHEMBL29571023 | 0.77 | KMT2A (0.54) | MEN1KMT2ANPSR1KIF11CYP1A2 | |
| SCHEMBL29570669 | 0.76 | KIF11 (0.47) | MEN1KMT2ANPSR1KIF11CYP1A2 | |
| SCHEMBL3650440 | 0.75 | KIF11 (0.46) | MEN1KMT2ANPSR1KIF11CYP1A2 | |
| SCHEMBL22612421 | 0.74 | MEN1 (0.54) | MEN1KMT2ANPSR1CYP1A2POLB | |
| SCHEMBL22397197 | 0.74 | MEN1 (0.54) | MEN1KMT2ANPSR1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1243723-C | N-phenylpropylcyclopentyl substituted glutaramide derivatives as NEP inhibitors of FSAD | PFIZER LTD (US) | 2006-03-01 | — | — | CN | disclosed |
| US-6849649-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| CN-1492852-A | N-phenylpropylcyclopentyl substituted glutaramide derivatives as NEP inhibitors of FSAD | ������ҩ������˾ | 2004-04-28 | — | — | CN | disclosed |
| EP-1373192-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | MEN1 3875/4885KMT2A 2144/4885NPSR1 366/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | MEN1 3854/4885KMT2A 2292/4885NPSR1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.